Sanofi has shared promising results from a mid-stage study of its investigational anti-CD40L antibody, frexalimab, in ...

Astellas' Marci English on managing the menopause; Clinigen’s Lorna Pender on treating rare diseases; the science behind ...

A new UK-wide report commissioned by Bristol Myers Squibb (BMS) and Shine Cancer Support has revealed disparities in cancer ...

Novartis has entered into an exclusive licence agreement with Arvinas for the development and commercialisation of the ...

In the face of the increasing threat from AMR, the recent Bioinfect 2024 conference offers five reasons to be hopeful ...

Gilead Sciences has announced that the National Institute for Health and Care Excellence (NICE) has recommended Veklury ...

Johnson & Johnson (J&J) has announced that it will be expanding its cardiovascular disease (CVD) capabilities by acquiring ...

It added that laboratory-based CYP2C19 genotype testing is its preferred option, followed by the Genedrive CYP2C19 ID Kit ...

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our planet. But are those connections working for or against your… ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved TMC Pharma’s Nulibry (fosdenopterin) to treat ...

AstraZeneca (AZ) has shared positive results from a late-stage study of its immunotherapy Imfinzi (durvalumab) in a subset of ...

Bristol Myers Squibb’s (BMS) Reblozyl (luspatercept) has been approved by the European Commission (EC) as a first-line ...